Stockreport

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort [Yahoo! Finance]

CERo Therapeutics Holdings, Inc.  (CERO) 
PDF evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO, Calif, Sept. 22, 2025 (GLOBE NEWSWIRE) -- [Read more]